Krka, d. d., Novo mesto Strategy, SWOT and Corporate Finance Report [Report Updated: 28072018] Prices from USD $175

07:22 EDT 28 Sep 2018 | BioPortfolio Reports

Krka, d. d., Novo mesto Strategy, SWOT and Corporate Finance Report


Summary


Krka, d. d., Novo mesto Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.


Key Highlights


Krka, d. d., Novo mesto Krka or 'the group', is a Sloveniabased generic pharmaceutical company. The group provides prescription pharmaceuticals, nonprescription products and animal health products. The group is also involved in the health resort business and provides tourist services. The group markets products under Atoris, Roswera, Ampril, Lorista, Septolete, Pikovit, Bilobil, Flebaven, Fypryst, Enroxil Amatib, Otoxolan and Flimabend brands, among otehrs. The group primarily operates in Europe, Middle East and Africa and the Americas. Krka is headquartered in Novo Mesto, Slovenia.


Scope


Detailed information on Krka, d. d., Novo mesto required for business and competitor intelligence needs

A study of the major internal and external factors affecting Krka, d. d., Novo mesto in the form of a SWOT analysis

An indepth view of the business model of Krka, d. d., Novo mesto including a breakdown and examination of key business segments

Intelligence on Krka, d. d., Novo mesto's mergers and acquisitions MandA, strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

News about Krka, d. d., Novo mesto, such as business expansion, restructuring, and contract wins

Large number of easytograsp charts and graphs that present important data and key trends


Reasons to buy


Gain understanding of Krka, d. d., Novo mesto and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Krka, d. d., Novo mesto as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Krka, d. d., Novo mesto's business structure, strategy and prospects.

More From BioPortfolio on "Krka, d. d., Novo mesto Strategy, SWOT and Corporate Finance Report [Report Updated: 28072018] Prices from USD $175"